BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23880140)

  • 1. Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism?
    Hu J; Liu Z; Wang X
    Med Hypotheses; 2013 Oct; 81(4):515-20. PubMed ID: 23880140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.
    Nieman KM; Kenny HA; Penicka CV; Ladanyi A; Buell-Gutbrod R; Zillhardt MR; Romero IL; Carey MS; Mills GB; Hotamisligil GS; Yamada SD; Peter ME; Gwin K; Lengyel E
    Nat Med; 2011 Oct; 17(11):1498-503. PubMed ID: 22037646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
    Menendez JA; Lupu R
    Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis.
    Adorno M; Cordenonsi M; Montagner M; Dupont S; Wong C; Hann B; Solari A; Bobisse S; Rondina MB; Guzzardo V; Parenti AR; Rosato A; Bicciato S; Balmain A; Piccolo S
    Cell; 2009 Apr; 137(1):87-98. PubMed ID: 19345189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.
    Ladanyi A; Mukherjee A; Kenny HA; Johnson A; Mitra AK; Sundaresan S; Nieman KM; Pascual G; Benitah SA; Montag A; Yamada SD; Abumrad NA; Lengyel E
    Oncogene; 2018 Apr; 37(17):2285-2301. PubMed ID: 29398710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers.
    Seagle BL; Eng KH; Dandapani M; Yeh JY; Odunsi K; Shahabi S
    Oncotarget; 2015 Jul; 6(21):18641-52. PubMed ID: 26215675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. There is no increase in frequency of somatic mutations in metastases compared with primary colorectal carcinomas with microsatellite instability.
    Barnetson R; Eckstein R; Robinson B; Schnitzler M
    Genes Chromosomes Cancer; 2003 Oct; 38(2):149-56. PubMed ID: 12939742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones.
    Ren YA; Mullany LK; Liu Z; Herron AJ; Wong KK; Richards JS
    Cancer Res; 2016 Apr; 76(8):2206-18. PubMed ID: 26964623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adipokine Apelin/APJ Pathway Promotes Peritoneal Dissemination of Ovarian Cancer Cells by Regulating Lipid Metabolism.
    Dogra S; Neelakantan D; Patel MM; Griesel B; Olson A; Woo S
    Mol Cancer Res; 2021 Sep; 19(9):1534-1545. PubMed ID: 34172534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance.
    Mukherjee A; Chiang CY; Daifotis HA; Nieman KM; Fahrmann JF; Lastra RR; Romero IL; Fiehn O; Lengyel E
    Cancer Res; 2020 Apr; 80(8):1748-1761. PubMed ID: 32054768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The metastatic phenotype shift toward myofibroblast of adipose-derived mesenchymal stem cells promotes ovarian cancer progression.
    Tang H; Chu Y; Huang Z; Cai J; Wang Z
    Carcinogenesis; 2020 Apr; 41(2):182-193. PubMed ID: 31046126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-17A promotes fatty acid uptake through the IL-17A/IL-17RA/p-STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte-rich microenvironment.
    Yu C; Niu X; Du Y; Chen Y; Liu X; Xu L; Iwakura Y; Ma X; Li Y; Yao Z; Deng W
    Cancer Immunol Immunother; 2020 Jan; 69(1):115-126. PubMed ID: 31802182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta.
    Rodriguez GC; Haisley C; Hurteau J; Moser TL; Whitaker R; Bast RC; Stack MS
    Gynecol Oncol; 2001 Feb; 80(2):245-53. PubMed ID: 11161867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?
    Menendez JA; Colomer R; Lupu R
    Med Hypotheses; 2005; 64(2):342-9. PubMed ID: 15607569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pro-tumoral behavior of omental adipocyte-derived fibroblasts in tumor microenvironment at the metastatic site of ovarian cancer.
    Iyoshi S; Yoshihara M; Nakamura K; Sugiyama M; Koya Y; Kitami K; Uno K; Mogi K; Tano S; Tomita H; Kajiwara K; Taki M; Yamaguchi S; Nawa A; Kajiyama H
    Int J Cancer; 2021 Dec; 149(11):1961-1972. PubMed ID: 34469585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer.
    Rynne-Vidal A; Au-Yeung CL; Jiménez-Heffernan JA; Pérez-Lozano ML; Cremades-Jimeno L; Bárcena C; Cristóbal-García I; Fernández-Chacón C; Yeung TL; Mok SC; Sandoval P; López-Cabrera M
    J Pathol; 2017 Jun; 242(2):140-151. PubMed ID: 28247413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 drives invasion by promoting integrin recycling.
    Muller PA; Caswell PT; Doyle B; Iwanicki MP; Tan EH; Karim S; Lukashchuk N; Gillespie DA; Ludwig RL; Gosselin P; Cromer A; Brugge JS; Sansom OJ; Norman JC; Vousden KH
    Cell; 2009 Dec; 139(7):1327-41. PubMed ID: 20064378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells.
    Roger L; Jullien L; Gire V; Roux P
    J Cell Sci; 2010 Apr; 123(Pt 8):1295-305. PubMed ID: 20332115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis.
    Capo-Chichi CD; Smith ER; Yang DH; Roland IH; Vanderveer L; Cohen C; Hamilton TC; Godwin AK; Xu XX
    Cancer; 2002 Oct; 95(8):1802-15. PubMed ID: 12365030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.
    Wu R; Baker SJ; Hu TC; Norman KM; Fearon ER; Cho KR
    Am J Pathol; 2013 Apr; 182(4):1391-9. PubMed ID: 23499052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.